A New Patent of Monoclonal Antibodies for the Treatment of Serious Diseases Research and Development Registered
On Dec. 21, 2012, one of our peer companies, Immunomedics, Inc. (Nasdaq:IMMU) announced that it has received notice its patent application for " Anti-CD19 antibodies " which would be issued as US patent No. 8,337,840 on Dec. 25, 2012. IMMU primarily attaches importance to the development of monoclonal antibody -based products for the targeted treatment of cancer, autoimmune and other serious diseases.
This patent will be expired until 2024; additionally, it also protects (19)-3s, a novel T-cell redirecting agent made as a DOCK-AND-LOCK™ (DNL™) complex using its patented platform technology.
The patent claims cover the use of specific humanized anti- CD19 monoclonal antibodies and fragments thereof for the treatment of autoimmune diseases. The antibodies and fragments thereof can be used alone, conjugated to at least one therapeutic agent or in combination with other humanized, chimeric, human or murine monoclonal antibodies, such as antibodies reactive with CD20, CD22, CD74 or HLA-DR.